xpertsystems/hconc002-sample

HC-ONC-002 — 肺癌合成队列是一个完全合成的多模态数据集，专注于肺癌研究。它涵盖了完整的临床路径，包括人口统计学、吸烟分层组织学（非小细胞肺癌的腺癌/鳞状细胞癌/大细胞癌和小细胞肺癌的局限期/广泛期）、AJCC第8版T/N/M分期与特定部位转移、全面的分子生物标志物（EGFR亚型、ALK/ROS1融合、KRAS G12C突破、BRAF V600E、MET外显子14跳跃、RET、NTRK、HER2、STK11、KEAP1、TP53）、PD-L1 TPS和CPS评分、肿瘤突变负荷、微卫星不稳定性、免疫治疗/靶向治疗时代的治疗方案（手术+辅助治疗、立体定向放疗、同步放化疗+度伐利尤单抗、靶向TKI、化疗-免疫联合治疗）、RECIST治疗反应（包括假性进展/超进展标志）、多模态成像（PET SUV/MTV、ctDNA检测+VAF）、免疫组化标记（TTF-1、p40、突触素）、不良事件（包括免疫相关不良事件表型）和生存结果（无进展生存期/总生存期，基于Weibull衍生事件时间）。数据集包含500名患者和116列变量，分为9个模块，旨在用于分析、建模、演示和教育，同时避免真实患者数据和隐私风险。数据集经过行业级校准，参考了SEER、TCGA、NCCN指南和临床试验数据，并提供了详细的验证报告和局限性说明。HC-ONC-002 — Lung Cancer Synthetic Cohort is a fully synthetic multimodal dataset focused on lung cancer research. It covers the full clinical pathway, including demographics, smoking-stratified histology (adenocarcinoma, squamous cell carcinoma and large cell carcinoma of non-small cell lung cancer, as well as limited-stage and extensive-stage small cell lung cancer), AJCC 8th Edition T/N/M staging and site-specific metastases, comprehensive molecular biomarkers (EGFR subtypes, ALK/ROS1 fusions, KRAS G12C mutation, BRAF V600E, MET exon 14 skipping, RET, NTRK, HER2, STK11, KEAP1, TP53), PD-L1 TPS and CPS scores, tumor mutational burden (TMB), microsatellite instability (MSI), treatment regimens in the immunotherapy and targeted therapy eras (surgery plus adjuvant therapy, stereotactic body radiation therapy, concurrent chemoradiotherapy plus durvalumab, targeted TKIs, chemoimmunotherapy combinations), RECIST treatment responses (including pseudoprogression and hyperprogression markers), multimodal imaging (PET SUV/MTV, ctDNA detection plus VAF), immunohistochemical markers (TTF-1, p40, synaptophysin), adverse events (including immune-related adverse event phenotypes) and survival outcomes (progression-free survival/overall survival, derived from Weibull-derived event times). The dataset includes 500 patients and 116 variables, divided into 9 modules, and is intended for analysis, modeling, demonstration and education, while avoiding real patient data and privacy risks. The dataset has been industry-calibrated by referencing SEER, TCGA, NCCN guidelines and clinical trial data, with detailed validation reports and limitation statements provided.